Incidence of Uveitis in Patients With Axial Spondylarthritis Treated With Biologics or Targeted Synthetics: A Systematic Review and Network Meta ‐Analysis
ConclusionAnti-TNF mAbs, JAKi, and anti –IL-17 appear protective against AU events in individuals with AxSpA, with no significant differences in risk of AU between treatments. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - April 13, 2024 Category: Rheumatology Authors: Katie Bechman,
Zijing Yang,
Maryam Adas,
Deepak Nagra,
Ali S U ğuzlar,
Mark D. Russell,
Nicky Wilson,
Sophia Steer,
Sam Norton,
James Galloway Tags: Full Length Source Type: research
Drug-induced lupus erythematosus in childhood: Case-based review
CONCLUSION: For children presenting with SLE features, proper drug history is crucial since DILE may be more frequent than anticipated. An association of the relevant drug with the symptoms, and resolution of symptoms on drug withdrawal provides evidence for the diagnosis of DILE.PMID:38580326 | DOI:10.1177/09612033241245078 (Source: Lupus)
Source: Lupus - April 5, 2024 Category: Rheumatology Authors: Ummusen Kaya Akca Seher Sener Ezgi Deniz Batu Zeynep Balik Ozge Basaran Yelda Bilginer Seza Ozen Source Type: research
Drug-induced lupus erythematosus in childhood: Case-based review
CONCLUSION: For children presenting with SLE features, proper drug history is crucial since DILE may be more frequent than anticipated. An association of the relevant drug with the symptoms, and resolution of symptoms on drug withdrawal provides evidence for the diagnosis of DILE.PMID:38580326 | DOI:10.1177/09612033241245078 (Source: Lupus)
Source: Lupus - April 5, 2024 Category: Rheumatology Authors: Ummusen Kaya Akca Seher Sener Ezgi Deniz Batu Zeynep Balik Ozge Basaran Yelda Bilginer Seza Ozen Source Type: research
Prevention of colon enlargement by TNF- α antagonist in a streptozotocin-induced diabetic rat model
CONCLUSIONS: TNF-α signaling in the colonic tissue of diabetic rats has a strong effect on tissue remodeling, leading to colon enlargement. TNF-α antagonists may be beneficial in preventing diabetic-related pathology in the colon in combination with anti-diabetic drugs.PMID:38572731 | DOI:10.14670/HH-18-735 (Source: Histology and Histopathology)
Source: Histology and Histopathology - April 4, 2024 Category: Cytology Authors: Tri Agusti Sholikah Dian Eurike Septyaningtrias Yustina Andwi Ari Sumiwi Muthmainah Muthmainah Rina Susilowati Source Type: research
Adalimumab in the management of psoriasis and psoriatic arthritis: Results from a Delphi investigation
CONCLUSION: Results from this Delphi study clearly show an overall consensus on the use of adalimumab in the management of PsO and PsA, particularly as first-choice for specific subpopulations (uveitis, IBD, hidradenitis suppurativa). Considering the cost-effectiveness of biosimilars within Italy, adalimumab may represent an effective and safe first-line treatment for patients with moderate-to-severe PsO or PsA, and a valid choice for switching after failure.PMID:38571927 | PMC:PMC10985702 | DOI:10.1515/rir-2024-0006 (Source: Cell Research)
Source: Cell Research - April 4, 2024 Category: Cytology Authors: Marco Matucci-Cerinic Francesco Ciccia Rosario Foti Alessandro Giunta Francesco Loconsole Francesca Prignano Rossana Scrivo Giampiero Girolomoni Source Type: research
Prevention of colon enlargement by TNF- α antagonist in a streptozotocin-induced diabetic rat model
CONCLUSIONS: TNF-α signaling in the colonic tissue of diabetic rats has a strong effect on tissue remodeling, leading to colon enlargement. TNF-α antagonists may be beneficial in preventing diabetic-related pathology in the colon in combination with anti-diabetic drugs.PMID:38572731 | DOI:10.14670/HH-18-735 (Source: Histology and Histopathology)
Source: Histology and Histopathology - April 4, 2024 Category: Cytology Authors: Tri Agusti Sholikah Dian Eurike Septyaningtrias Yustina Andwi Ari Sumiwi Muthmainah Muthmainah Rina Susilowati Source Type: research
Additional Data in Expanded Patient Populations and New Indications Support the Practice of Biosimilar-to-Biosimilar Switching
AbstractAs of 31 December, 2023, 31 observational studies have been published, including a total of 6081 patients who underwent a switch from one biosimilar to another biosimilar of the same reference biologic. Most studies evaluated infliximab, while a smaller number evaluated adalimumab, rituximab or etanercept. Indications studied now include sarcoidosis, as well as the indications previously reported of rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis/ankylosing spondylitis and inflammatory bowel disease (Crohn ’s disease and ulcerative colitis). This updated data set includes eight additional studi...
Source: BioDrugs - March 23, 2024 Category: Drugs & Pharmacology Source Type: research
The First Case of a Korean Patient with a Mutation-Confirmed Tumor Necrosis Factor Receptor-Associated Periodic Syndrome
Yonsei Med J. 2024 Apr;65(4):241-245. doi: 10.3349/ymj.2023.0366.ABSTRACTTumor necrosis factor receptor-associated periodic syndrome (TRAPS, OMIM: #142680) is a rare autoinflammatory disease (AID) with recurrent febrile episodes. To our knowledge, we report herein the first case of a patient with TRAPS in South Korea whose symptoms included fever, arthralgia, abdominal pain, rash, myalgia, cough, and lymphadenopathy. A pathogenic de novo mutation, c.175T>C (p.Cys59Arg), in the tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) gene, was confirmed by gene sequencing. The patient has been with tocilizumab (an...
Source: Yonsei Medical Journal - March 22, 2024 Category: Universities & Medical Training Authors: Seok-Jin Lee Jee Yeon Baek Ji Young Lee Ji-Man Kang Jong Gyun Ahn Source Type: research
Effectiveness and safety of biological and target synthetic drugs treatment for psoriatic arthritis: a systematic review with network meta-analysis
CONCLUSIONS: In conclusion, based on the balance between efficacy and safety, Secukinumab and Adalimumab may be the preferred options among the evaluated drugs for treating patients with PsA. However, caution is necessary when interpreting the safety findings, as they are supported by evidence of low to very low certainty. Consequently, the balance between benefits and potential risks may change as new safety evaluation studies become available.PROTOCOL REGISTRATION: PROSPERO: CRD42022315577.PMID:38515177 | DOI:10.1186/s42358-024-00361-3 (Source: Adv Data)
Source: Adv Data - March 22, 2024 Category: Epidemiology Authors: Thais Montezuma Livia Fernandes Probst Matheus Oliveira Almeida Source Type: research
The First Case of a Korean Patient with a Mutation-Confirmed Tumor Necrosis Factor Receptor-Associated Periodic Syndrome
Yonsei Med J. 2024 Apr;65(4):241-245. doi: 10.3349/ymj.2023.0366.ABSTRACTTumor necrosis factor receptor-associated periodic syndrome (TRAPS, OMIM: #142680) is a rare autoinflammatory disease (AID) with recurrent febrile episodes. To our knowledge, we report herein the first case of a patient with TRAPS in South Korea whose symptoms included fever, arthralgia, abdominal pain, rash, myalgia, cough, and lymphadenopathy. A pathogenic de novo mutation, c.175T>C (p.Cys59Arg), in the tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) gene, was confirmed by gene sequencing. The patient has been with tocilizumab (an...
Source: Yonsei Medical Journal - March 22, 2024 Category: Universities & Medical Training Authors: Seok-Jin Lee Jee Yeon Baek Ji Young Lee Ji-Man Kang Jong Gyun Ahn Source Type: research
Effectiveness and safety of biological and target synthetic drugs treatment for psoriatic arthritis: a systematic review with network meta-analysis
CONCLUSIONS: In conclusion, based on the balance between efficacy and safety, Secukinumab and Adalimumab may be the preferred options among the evaluated drugs for treating patients with PsA. However, caution is necessary when interpreting the safety findings, as they are supported by evidence of low to very low certainty. Consequently, the balance between benefits and potential risks may change as new safety evaluation studies become available.PROTOCOL REGISTRATION: PROSPERO: CRD42022315577.PMID:38515177 | DOI:10.1186/s42358-024-00361-3 (Source: Adv Data)
Source: Adv Data - March 22, 2024 Category: Epidemiology Authors: Thais Montezuma Livia Fernandes Probst Matheus Oliveira Almeida Source Type: research
The First Case of a Korean Patient with a Mutation-Confirmed Tumor Necrosis Factor Receptor-Associated Periodic Syndrome
Yonsei Med J. 2024 Apr;65(4):241-245. doi: 10.3349/ymj.2023.0366.ABSTRACTTumor necrosis factor receptor-associated periodic syndrome (TRAPS, OMIM: #142680) is a rare autoinflammatory disease (AID) with recurrent febrile episodes. To our knowledge, we report herein the first case of a patient with TRAPS in South Korea whose symptoms included fever, arthralgia, abdominal pain, rash, myalgia, cough, and lymphadenopathy. A pathogenic de novo mutation, c.175T>C (p.Cys59Arg), in the tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) gene, was confirmed by gene sequencing. The patient has been with tocilizumab (an...
Source: Yonsei Medical Journal - March 22, 2024 Category: Universities & Medical Training Authors: Seok-Jin Lee Jee Yeon Baek Ji Young Lee Ji-Man Kang Jong Gyun Ahn Source Type: research
The First Case of a Korean Patient with a Mutation-Confirmed Tumor Necrosis Factor Receptor-Associated Periodic Syndrome
Yonsei Med J. 2024 Apr;65(4):241-245. doi: 10.3349/ymj.2023.0366.ABSTRACTTumor necrosis factor receptor-associated periodic syndrome (TRAPS, OMIM: #142680) is a rare autoinflammatory disease (AID) with recurrent febrile episodes. To our knowledge, we report herein the first case of a patient with TRAPS in South Korea whose symptoms included fever, arthralgia, abdominal pain, rash, myalgia, cough, and lymphadenopathy. A pathogenic de novo mutation, c.175T>C (p.Cys59Arg), in the tumor necrosis factor receptor superfamily member 1A (TNFRSF1A) gene, was confirmed by gene sequencing. The patient has been with tocilizumab (an...
Source: Yonsei Medical Journal - March 22, 2024 Category: Universities & Medical Training Authors: Seok-Jin Lee Jee Yeon Baek Ji Young Lee Ji-Man Kang Jong Gyun Ahn Source Type: research
